SLC25A39 potentiates the RXFP1/cAMP/PKA/CREB axis to drive metabolic reprogramming and tumor progression in ovarian cancer.
9 affiliations
- 1Gynecological Department, Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Chengde, 067000, Hebei, China.
- 2Gynecological Department, The Second Clinical Medical College of Inner Mongolia Minzu University (Inner Mongolia Forestry General Hospital), Hulun Buir, 022150, Inner Mongolia, China.
- 3Oncology Department, Chengde Central Hospital, Chengde, 067000, Hebei, China.
- 4Nursing Department, Chengde Medical University, Chengde, 067000, Hebei, China.
- 5Gynecological Department, Shuangluan District People's Hospital of Chengde City, Chengde, 067000, Hebei, China.
- 6Gynecological Department, Chengde Central Hospital, Chengde, 067000, Hebei, China.
- 7Gynecological Department, Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Chengde, 067000, Hebei, China. [email protected].
- 8Gynecological Department, Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Chengde, 067000, Hebei, China. [email protected].
- 9Gynecological Department, Huadu District People's Hospital of Guangzhou, Guangzhou, 510800, Guangdong, China. [email protected].
Abstract
The mitochondrial transporter SLC25A39 mediates GSH transport from the cytosol to mitochondria and is essential for maintaining mitochondrial oxidative homeostasis and function. However, its exact molecular mechanism in ovarian cancer has not yet been elucidated. In the present work, protein and mRNA expression levels were measured using database analysis, IHC, IF, Western blot, and RT-qPCR. Cell proliferation, apoptosis, and migration capabilities were assessed by functional assays. Mitochondrial function was assessed by measuring glutathione reductase activity, ROS, MMP, and mPTP opening status. Energy metabolism was quantified through ATP content, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR). Transcriptomics, metabolomics and proteomics analyses combined with ChIP and experiments on gain and loss of function were carried out to explore associated signaling pathways, with final validation conducted in mouse models. The results show that SLC25A39 expression was upregulated in ovarian cancer tissues. Ovarian cancer cell proliferation and migration were markedly enhanced, while apoptosis was suppressed, upon SLC25A39 overexpression. Furthermore, SLC25A39 overexpression drove significant metabolic reprogramming, characterized by elevated GSH levels, reduced ROS production, increased MMP, closed mPTP, augmented ATP generation, and concurrently enhanced oxidative phosphorylation (OCR) and glycolytic flux (ECAR). Mechanistically, SLC25A39 potentiated the RXFP1/cAMP/PKA/CREB signaling axis by remodeling the intracellular redox and energy microenvironment, thereby driving metabolic reprogramming and promoting cell survival in ovarian cancer. Critically, CREB specifically bound to the SLC25A39 promoter, establishing a reciprocal reinforcing transcriptional regulatory circuit. These findings were further validated in vivo through animal experiments. In conclusion, SLC25A39 orchestrates metabolic reprogramming and promotes tumor growth by potentiating the RXFP1/cAMP/PKA/CREB axis, therefore positioning it as a promising therapeutic target for ovarian cancer.
Graphical Abstract: The graphical abstract was obtained from Stock (https://www.storkapp.me/aifigure/app.php).
Supplementary information: The online version contains supplementary material available at https://doi.org/10.1007/s10565-026-10236-6.
Related
- 944 Succinate-based metabolic reprogramming of innate and adaptive immunity for ovarian cancer immunotherapy
- DEGS1-mTORC1-driven lipid metabolic reprogramming fuels rhabdomyosarcoma progression and unveils a therapeutic vulnerability
- KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma
- MCT4-Associated Lactate Export Defines Myeloid Metabolic Reprogramming during Head and Neck Cancer Progression
- SLC16A13 Promotes Malignant Progression in Glioma via Metabolic Reprogramming and Disruption of Monocarboxylate Homeostasis.
BibTeX
@article{tian2026slc25a39,
title = {{SLC25A39 potentiates the RXFP1/cAMP/PKA/CREB axis to drive metabolic reprogramming and tumor progression in ovarian cancer.}},
author = {Tian Tian and Jiming Bai and Qian Li and Qing Li and Shumin Kang and Qiong Wu and Penghua Cui and Suwei Lan},
journal = {Cell biology and toxicology},
year = {2026},
month = aug,
doi = {10.1007/s10565-026-10236-6},
url = {https://europepmc.org/article/MED/42957878},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - SLC25A39 potentiates the RXFP1/cAMP/PKA/CREB axis to drive metabolic reprogramming and tumor progression in ovarian cancer.
AU - Tian Tian
AU - Jiming Bai
AU - Qian Li
AU - Qing Li
AU - Shumin Kang
AU - Qiong Wu
AU - Penghua Cui
AU - Suwei Lan
PY - 2026
DA - 2026/08/03
JO - Cell biology and toxicology
DO - 10.1007/s10565-026-10236-6
UR - https://europepmc.org/article/MED/42957878
AB - The mitochondrial transporter SLC25A39 mediates GSH transport from the cytosol to mitochondria and is essential for maintaining mitochondrial oxidative homeostasis and function. However, its exact molecular mechanism in ovarian cancer has not yet been elucidated. In the present work, protein and mRNA expression levels were measured using database analysis, IHC, IF, Western blot, and RT-qPCR. Cell proliferation, apoptosis, and migration capabilities were assessed by functional assays. Mitochondrial function was assessed by measuring glutathione reductase activity, ROS, MMP, and mPTP opening status. Energy metabolism was quantified through ATP content, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR). Transcriptomics, metabolomics and proteomics analyses combined with ChIP and experiments on gain and loss of function were carried out to explore associated signaling pathways, with final validation conducted in mouse models. The results show that SLC25A39 expression was upregulated in ovarian cancer tissues. Ovarian cancer cell proliferation and migration were markedly enhanced, while apoptosis was suppressed, upon SLC25A39 overexpression. Furthermore, SLC25A39 overexpression drove significant metabolic reprogramming, characterized by elevated GSH levels, reduced ROS production, increased MMP, closed mPTP, augmented ATP generation, and concurrently enhanced oxidative phosphorylation (OCR) and glycolytic flux (ECAR). Mechanistically, SLC25A39 potentiated the RXFP1/cAMP/PKA/CREB signaling axis by remodeling the intracellular redox and energy microenvironment, thereby driving metabolic reprogramming and promoting cell survival in ovarian cancer. Critically, CREB specifically bound to the SLC25A39 promoter, establishing a reciprocal reinforcing transcriptional regulatory circuit. These findings were further validated in vivo through animal experiments. In conclusion, SLC25A39 orchestrates metabolic reprogramming and promotes tumor growth by potentiating the RXFP1/cAMP/PKA/CREB axis, therefore positioning it as a promising therapeutic target for ovarian cancer. Graphical Abstract: The graphical abstract was obtained from Stock (https://www.storkapp.me/aifigure/app.php). Supplementary information: The online version contains supplementary material available at https://doi.org/10.1007/s10565-026-10236-6.
SN - 0742-2091
SN - 1573-6822
ER -